Tarsus Pharmaceuticals Inc [TARS] stock is trading at $81.88, down -0.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TARS shares have lost -0.30% over the last week, with a monthly amount glided 2.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tarsus Pharmaceuticals Inc [NASDAQ: TARS] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $100. Previously, Mizuho started tracking the stock with Outperform rating on November 20, 2025, and set its price target to $100. Goldman initiated its recommendation with a Neutral and recommended $19 as its price target on November 20, 2023. William Blair started tracking with an Outperform rating for this stock on July 18, 2023, and assigned it a price target of $44. In a note dated May 18, 2023, Guggenheim initiated a Buy rating.
Tarsus Pharmaceuticals Inc [TARS] stock has fluctuated between $38.51 and $85.25 over the past year. Currently, Wall Street analysts expect the stock to reach $84.75 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $81.88 at the most recent close of the market. An investor can expect a potential return of 3.51% based on the average TARS price forecast.
Analyzing the TARS fundamentals
Tarsus Pharmaceuticals Inc [NASDAQ:TARS] reported sales of 366.10M for the trailing twelve months, which represents a growth of 146.68%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.22%, and Net Profit Margin reading is -0.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.26 and Total Capital is -0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 81.18 points at the first support level, and at 80.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 83.26, and for the 2nd resistance point, it is at 84.64.
Ratios To Look Out For
For context, Tarsus Pharmaceuticals Inc’s Current Ratio is 4.29. Further, the Quick Ratio stands at 4.25, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 9.49, the price to book ratio is 10.37.
Transactions by insiders
Recent insider trading involved Azamian Bobak R., President/CEO and Board Chair, that happened on Dec 24 ’25 when 6000.0 shares were sold. OFFICER, BOBAK AZAMIAN completed a deal on Dec 24 ’25 to buy 6000.0 shares. Meanwhile, Chief Human Resources Officer Whitfield Dianne C. sold 7397.0 shares on Dec 16 ’25.
